Premium
A relationship between unrecognized anaemia and the development of type 2 diabetes mellitus in patient with cardiovascular risks
Author(s) -
Choi Byoung Geol,
Kim Jung Boone,
Rha SeungWoon,
Kim Suhng Wook,
Lee Min Woo,
Lee Michael S.,
Choi Se Yeon,
Byun Jae Kyeong,
Cha Jinah,
Na Jin Oh,
Choi Cheol Ung,
Park Chang Gyu,
Seo Hong Seog,
Oh Dong Joo,
Hong Sunghoi
Publication year - 2021
Publication title -
clinical and experimental pharmacology and physiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.752
H-Index - 103
eISSN - 1440-1681
pISSN - 0305-1870
DOI - 10.1111/1440-1681.13440
Subject(s) - medicine , hazard ratio , confidence interval , propensity score matching , incidence (geometry) , diabetes mellitus , clinical endpoint , population , confounding , pediatrics , anemia , randomized controlled trial , endocrinology , physics , environmental health , optics
Studies on anaemia in diabetic patients are well known. However, the data regarding association of anaemia on the development of diabetes mellitus (DM) are very limited. We aimed to evaluate the association of anaemia on the development of DM and major clinical outcomes in a series of the Korean population during 5‐year clinical follow‐up. The patients were retrospectively enrolled using the electronic database of Korea University Guro Hospital from January 2004 to February 2013. A total of 17 515 subjects without a history of DM were analysed. The World Health Organization definition of anaemia was used. Patients were divided into the anaemia group (n = 2907 patients) and the non‐anaemia group (n = 14 608 patients). The primary endpoint was the development of DM. To adjust baseline potential confounders, a propensity score matching (PSM) analysis was performed. After PSM analysis, two matched groups (2731 pairs) were generated and their baselines characteristics were balanced. During 5‐year follow‐up, the anaemia group had a higher incidence of type 2 DM (10.7% vs 7.7%; hazard ratio [HR], 1.356; 95% confidence interval [CI], 1.021–1.802; P = .035), and total death (2.6% vs 1.2%; HR, 2.449; 95% CI, 1.337–4.486; P = .004) compared to the non‐anaemia group. In the present study, anaemia was associated with higher rate of the development of DM and mortality during 5‐year clinical follow‐up. A randomized trial is needed to determine whether this results can be reproducible or not for the final conclusion.